CRC will attend the Clinical Trials on Alzheimer’s Disease Conference (CTAD), November 16-19, 2026 in Boston, MA. Our team looks forward to connecting with sponsors and industry partners working to advance therapies for Alzheimer’s disease.
Planning an Alzheimer’s study means balancing scientific requirements with practical considerations for sites, participants, and their caregivers. CRC’s experience over 20 years in CNS includes Alzheimer’s research that informs how our teams help sponsors work through those decisions, from assessment needs to study execution.
Whether you’re planning an upcoming study, evaluating CRO partners, or considering where additional expertise would be useful, our team welcomes the opportunity to learn about your program and the support you need.
Meet the CRC Team at CTAD
Thomas Hochadel, Pharm.D.
Dr. Hochadel has 30+ years of Alzheimer’s research experience, managing and overseeing 30+ clinical trials. These range from symptomatic and disease-modifying treatments to behavioral therapies, covering Phase I-III trials. His work includes managing studies across diverse populations, from Age-Associated Memory Impairment to severe Alzheimer’s, in various care settings.
Jim Free
Mr. Free has 20+ years of experience building specialized site networks for complex indications, including agitation in dementia, Rett syndrome, anxiety, and treatment-resistant depression. He has led successful programs and supported multiple IND, NDA, and ANDA submissions.
Annie Speno
Ms. Speno is an industry leader with more than 15 years of experience and possesses extensive knowledge in the clinical trials industry, including sponsor relations and working within the central nervous system sector.
SCHEDULE A CONVERSATION
If you’re planning an Alzheimer’s study or considering support for an upcoming program, our team would be happy to connect at CTAD. Complete the form below to schedule a conversation about your priorities and what would be useful to your team.
